Sano

Sano Genetics provides a comprehensive platform for clinical trial recruitment, genetic testing, and long-term patient engagement in precision medicine research. The platform automates workflows across the research process, offering services including study design and protocol development, recruitment support through online campaigns and patient advocacy networks, prescreening and digital consent, electronic medical record retrieval, at-home saliva DNA testing with end-to-end logistics and genetic counseling, and customized patient engagement programs. Sano supports multi-country, multi-language programs across disease areas including lupus, Parkinson's, MASH, ALS, and Long COVID. The platform is ISO27001 certified, HIPAA and GDPR compliant, with options for dedicated cloud infrastructure. Founded in 2016 and headquartered in London, United Kingdom, Sano has raised approximately $26.5 million in Series A funding from investors including Plural, MMC Ventures, Y Combinator, and Cambridge Enterprise.